The company indicated it expects to begin an on-body artificial pancreas trial this fall. This is a quote, "And in terms of functionality of our system, we don't want to give too much away, but I think I have said to you before that we definitely will have more than predictive low suspend ... we really want to bring value to the market when we launch, so that's our goal." The company has really ramped up its efforts on engineering. A Bluetooth pod and PDM is in the works, and trials are under way on a system that will handle concentrated insulins, like U-500 and U-200. What was not said is how soon we might be able to control our delivery via smartphone and eliminate having to carry the PDM, as Dexcom has been able to do with its glucose monitors. However, integration with Dexcom is part of the new system, which is expected to be debuted at the ADA convention in San Diego next year.